Paying down more debt, Takeda offloads prescription drug portfolio for $562 million
It’s been two years since Takeda’s $62 billion Shire buyout, and the Tokyo biotech is still restructuring.
The company struck a deal with Germany-based Cheplapharm to divest some non-core prescription products for an upfront payment of $562 million. The portfolio — which includes cardiovascular, metabolic and anti-inflammatory drugs sold mostly in Europe and Canada — doesn’t fit in with Takeda’s post-Shire vision. The biotech has since shifted its focus to gastroenterology (GI), rare diseases, plasma-derived therapies, oncology and neuroscience.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.